Profile photo Marnix Lam

Marnix Lam

Full Professor

Strategic program(s):

Biography

Marnix Lam (1975) studied Pharmaceutical sciences (passed with distinction) and Medicine at Utrecht University. He became a resident in Nuclear Medicine, respectively Radiology and finalized his PhD thesis (2009) on radionuclide therapy in prostate cancer patients with metastatic bone pain. This was followed by a two-year postdoctoral fellowship at Stanford University School of Medicine, USA. In 2016 he was appointed Professor of Nuclear Medicine.
Translational research in molecular medicine has been the scope of his scientific work, with a focus on oncology. Bringing new radiopharmaceuticals to clinical practice. This specifically resulted in the introduction of new oncological treatment modalities in the Netherlands, such as bone seeking radiopharmaceuticals for the palliation of metastatic bone pain (Sm-153-EDTMP, Re-188-HEDP) and radioembolization for treatment of hepatic malignancies (Y-90 and Ho-166 microspheres). Current research is focussed on dosimetry of therapeutic radiopharmaceuticals, image-guided treatment technology, alfa- and beta-emitting isotopes for therapeutic purposes, intra-arterial and intra-tumor treatment approaches, and radio-immunotherapy.

Strategic program(s):

Contact

Research groups

Nuclear theranostics research

Research aim

With nuclear theranostics we aim to develop radiopharmaceuticals to improve the disease diagnosis and therapy, including clinical translation for direct impact. Disease areas of interest are (childhood) cancer, neurology and infectious diseases.
Go to group

Primary Liver Tumors research group

Research aim

To improve surveillance, diagnostics, treatment, and outcome for patients with primary liver tumors (hepatocellular carcinoma and cholangiocarcinoma) by interdisciplinary and (inter-)national collaborative research
Go to group

Recent publications

90Y-/166Ho- ‘Radiation lobectomy’ for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics Daan Andel, Lotte van den Bent, Marnix Lam, Maarten Smits, Isaac Quintus Molenaar, Joep de Bruijne, Miangela Marie Laclé, Onno Kranenburg, Inne Borel Rinkes, Jeroen Hagendoorn
JHEP Reports, 2024, vol. 6, p.1-9
Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma Martijn E H M Wagemans, Britt Kunnen, Martina Stella, Rob van Rooij, Marnix G E H Lam, Hugo W A M de Jong, Arthur J A T Braat
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024, vol. 65, p.272-278
Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [ 166Ho]-Scout Over [ 99mTc]MAA in a Prospective Cohort Study Martijn E H M Wagemans, Arthur J A T Braat, Rob van Rooij, Maarten L J Smits, Rutger C G Bruijnen, Jip F Prince, Guus M Bol, Hugo W A M de Jong, Marnix G E H Lam
Cardiovascular and Interventional Radiology, 2024, vol. 47, p.443-450
Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases Riad Salem, Etienne Garin, Eveline Boucher, Kirk Fowers, Marnix Lam, Siddharth Padia, William Harris
Oncologist, 2024, vol. 29, p.681-689
An international phantom study of inter-site variability in Technetium-99m image quantification Grace Keane, Rob van Rooij, Marnix Lam, S Cheenu Kappadath, Bilal Kovan, Stephanie Leon, Matthew Dreher, Kirk Fowers, Hugo de Jong
EJNMMI physics, 2024, vol. 11
Safety and efficacy of Holmium-166 selective internal radiotherapy of primary and secondary liver cancer confirmed by real-world data Victor Schulze-Zachau, Gontran Verset, Pieter De Bondt, Katrien De Keukeleire, Falk Gühne, Martin Heuschkel, Ralf Thorsten Hoffmann, Elena Bozzi, Rosa Sciuto, Marnix Lam, Jordi Deportós Moreno, Roxane Debrus, Christoph J. Zech
Frontiers in oncology, 2024, vol. 14

External positions

Adviseur, spreker - Advies, spreken op (inter)nationale gelegenheden, samenwerking op gebied van klinisch onderzoek - Novartis

Scientific Advisory Board - Wetenschappelijk advies - OncoSil Medical Limited

Adviseur, spreker - Advies, spreker op (inter)nationale gelegenheden, wetenschappelijke samenwerking - Terumo/Quirem Medical B.V.

Adviseur - Advies, wetenschappelijke samenwerking - Boston Scientific